AAPL289.85+0.49 (+0.17%) ▲|ABBV249.67-1.97 (-0.78%) ▼|ABT92.66+1.92 (+2.11%) ▲|ACN126.81+2.37 (+1.90%) ▲|ADBE208.69+3.67 (+1.79%) ▲|AMAT688.39-34.62 (-4.79%) ▼|AMD560.27-20.64 (-3.55%) ▼|AMGN362.83+0.71 (+0.19%) ▲|AMT165.40+1.83 (+1.12%) ▲|AMZN236.24-2.11 (-0.88%) ▼|AVGO370.19-7.56 (-2.00%) ▼|AXP339.32+1.07 (+0.32%) ▲|BA218.29+1.82 (+0.84%) ▲|BAC57.45+0.47 (+0.82%) ▲|BKNG180.02+1.78 (+1.00%) ▲|BLK964.15+2.59 (+0.27%) ▲|BMY57.22-0.40 (-0.69%) ▼|BNY145.09+0.48 (+0.33%) ▲|BRK-B500.49+0.10 (+0.02%) ▲|C139.12-0.84 (-0.60%) ▼|CAT1,038.13-26.77 (-2.51%) ▼|CL91.78+0.10 (+0.11%) ▲|CMCSA24.00-0.56 (-2.26%) ▼|COF202.06+1.44 (+0.72%) ▲|COP104.00+0.04 (+0.04%) ▲|COST925.00-10.47 (-1.12%) ▼|CRM163.56+6.90 (+4.40%) ▲|CSCO116.72-0.74 (-0.63%) ▼|CVS103.58+0.13 (+0.13%) ▲|CVX166.48+0.72 (+0.43%) ▲|DE625.06-9.27 (-1.46%) ▼|DHR191.76+1.28 (+0.67%) ▲|DIS97.00+0.75 (+0.77%) ▲|DUK126.33-0.25 (-0.20%) ▼|EMR141.55-1.61 (-1.12%) ▼|FDX315.28+2.15 (+0.69%) ▲|GD359.74+5.50 (+1.55%) ▲|GE374.75+1.02 (+0.27%) ▲|GEV1,151.69-23.17 (-1.97%) ▼|GILD125.78-0.56 (-0.44%) ▼|GM77.20+0.12 (+0.16%) ▲|GOOG353.82+0.49 (+0.14%) ▲|GOOGL357.16-0.22 (-0.06%) ▼|GS1,016.00+4.63 (+0.46%) ▲|HD354.31+1.63 (+0.46%) ▲|HON224.85+0.95 (+0.42%) ▲|IBM286.68+5.47 (+1.95%) ▲|INTC135.25-4.38 (-3.14%) ▼|INTU270.82+9.82 (+3.76%) ▲|ISRG401.82+4.14 (+1.04%) ▲|JNJ252.95-1.02 (-0.40%) ▼|JPM328.29+0.96 (+0.29%) ▲|KO81.62+0.35 (+0.42%) ▲|LIN519.07+0.13 (+0.02%) ▲|LLY1,195.38-4.05 (-0.34%) ▼|LMT518.83+9.37 (+1.84%) ▲|LOW223.16+2.67 (+1.21%) ▲|LRCX408.21-25.12 (-5.80%) ▼|MA514.50+0.90 (+0.18%) ▲|MCD269.55-0.76 (-0.28%) ▼|MDLZ58.72+0.88 (+1.52%) ▲|MDT79.54+1.31 (+1.67%) ▲|META604.43+41.14 (+7.30%) ▲|MMM160.68-1.23 (-0.76%) ▼|MO72.15+0.20 (+0.28%) ▲|MRK126.86-1.64 (-1.28%) ▼|MS209.85+0.81 (+0.39%) ▲|MSFT376.53+3.51 (+0.94%) ▲|MU1,089.58-64.71 (-5.61%) ▼|NEE87.36-0.37 (-0.42%) ▼|NFLX72.72+1.32 (+1.85%) ▲|NKE42.12+1.08 (+2.62%) ▲|NOW102.66+3.39 (+3.41%) ▲|NVDA195.25-4.84 (-2.42%) ▼|ORCL145.70-0.96 (-0.65%) ▼|PEP139.18+3.78 (+2.79%) ▲|PFE24.11+0.33 (+1.37%) ▲|PG146.41-0.11 (-0.08%) ▼|PLTR123.25+6.58 (+5.64%) ▲|PM179.11-1.74 (-0.96%) ▼|QCOM184.51-0.29 (-0.15%) ▼|RTX189.98+0.32 (+0.17%) ▲|SBUX102.45+0.26 (+0.25%) ▲|SCHW93.35+1.15 (+1.25%) ▲|SO95.66-0.03 (-0.03%) ▼|SPG221.57-2.15 (-0.96%) ▼|T20.81+0.12 (+0.56%) ▲|TMO505.28+4.37 (+0.87%) ▲|TMUS170.88+3.15 (+1.88%) ▲|TSLA422.87+2.27 (+0.54%) ▲|TXN302.33+4.26 (+1.43%) ▲|UBER72.75+0.64 (+0.89%) ▲|UNH418.13+2.78 (+0.67%) ▲|UNP272.74+0.84 (+0.31%) ▲|UPS108.25+0.85 (+0.79%) ▲|USB60.96+0.55 (+0.90%) ▲|V342.20-0.39 (-0.11%) ▼|VZ42.38+0.07 (+0.17%) ▲|WFC84.21+1.57 (+1.90%) ▲|WMT107.91-5.35 (-4.72%) ▼|XOM137.00+0.52 (+0.38%) ▲|AAPL289.85+0.49 (+0.17%) ▲|ABBV249.67-1.97 (-0.78%) ▼|ABT92.66+1.92 (+2.11%) ▲|ACN126.81+2.37 (+1.90%) ▲|ADBE208.69+3.67 (+1.79%) ▲|AMAT688.39-34.62 (-4.79%) ▼|AMD560.27-20.64 (-3.55%) ▼|AMGN362.83+0.71 (+0.19%) ▲|AMT165.40+1.83 (+1.12%) ▲|AMZN236.24-2.11 (-0.88%) ▼|AVGO370.19-7.56 (-2.00%) ▼|AXP339.32+1.07 (+0.32%) ▲|BA218.29+1.82 (+0.84%) ▲|BAC57.45+0.47 (+0.82%) ▲|BKNG180.02+1.78 (+1.00%) ▲|BLK964.15+2.59 (+0.27%) ▲|BMY57.22-0.40 (-0.69%) ▼|BNY145.09+0.48 (+0.33%) ▲|BRK-B500.49+0.10 (+0.02%) ▲|C139.12-0.84 (-0.60%) ▼|CAT1,038.13-26.77 (-2.51%) ▼|CL91.78+0.10 (+0.11%) ▲|CMCSA24.00-0.56 (-2.26%) ▼|COF202.06+1.44 (+0.72%) ▲|COP104.00+0.04 (+0.04%) ▲|COST925.00-10.47 (-1.12%) ▼|CRM163.56+6.90 (+4.40%) ▲|CSCO116.72-0.74 (-0.63%) ▼|CVS103.58+0.13 (+0.13%) ▲|CVX166.48+0.72 (+0.43%) ▲|DE625.06-9.27 (-1.46%) ▼|DHR191.76+1.28 (+0.67%) ▲|DIS97.00+0.75 (+0.77%) ▲|DUK126.33-0.25 (-0.20%) ▼|EMR141.55-1.61 (-1.12%) ▼|FDX315.28+2.15 (+0.69%) ▲|GD359.74+5.50 (+1.55%) ▲|GE374.75+1.02 (+0.27%) ▲|GEV1,151.69-23.17 (-1.97%) ▼|GILD125.78-0.56 (-0.44%) ▼|GM77.20+0.12 (+0.16%) ▲|GOOG353.82+0.49 (+0.14%) ▲|GOOGL357.16-0.22 (-0.06%) ▼|GS1,016.00+4.63 (+0.46%) ▲|HD354.31+1.63 (+0.46%) ▲|HON224.85+0.95 (+0.42%) ▲|IBM286.68+5.47 (+1.95%) ▲|INTC135.25-4.38 (-3.14%) ▼|INTU270.82+9.82 (+3.76%) ▲|ISRG401.82+4.14 (+1.04%) ▲|JNJ252.95-1.02 (-0.40%) ▼|JPM328.29+0.96 (+0.29%) ▲|KO81.62+0.35 (+0.42%) ▲|LIN519.07+0.13 (+0.02%) ▲|LLY1,195.38-4.05 (-0.34%) ▼|LMT518.83+9.37 (+1.84%) ▲|LOW223.16+2.67 (+1.21%) ▲|LRCX408.21-25.12 (-5.80%) ▼|MA514.50+0.90 (+0.18%) ▲|MCD269.55-0.76 (-0.28%) ▼|MDLZ58.72+0.88 (+1.52%) ▲|MDT79.54+1.31 (+1.67%) ▲|META604.43+41.14 (+7.30%) ▲|MMM160.68-1.23 (-0.76%) ▼|MO72.15+0.20 (+0.28%) ▲|MRK126.86-1.64 (-1.28%) ▼|MS209.85+0.81 (+0.39%) ▲|MSFT376.53+3.51 (+0.94%) ▲|MU1,089.58-64.71 (-5.61%) ▼|NEE87.36-0.37 (-0.42%) ▼|NFLX72.72+1.32 (+1.85%) ▲|NKE42.12+1.08 (+2.62%) ▲|NOW102.66+3.39 (+3.41%) ▲|NVDA195.25-4.84 (-2.42%) ▼|ORCL145.70-0.96 (-0.65%) ▼|PEP139.18+3.78 (+2.79%) ▲|PFE24.11+0.33 (+1.37%) ▲|PG146.41-0.11 (-0.08%) ▼|PLTR123.25+6.58 (+5.64%) ▲|PM179.11-1.74 (-0.96%) ▼|QCOM184.51-0.29 (-0.15%) ▼|RTX189.98+0.32 (+0.17%) ▲|SBUX102.45+0.26 (+0.25%) ▲|SCHW93.35+1.15 (+1.25%) ▲|SO95.66-0.03 (-0.03%) ▼|SPG221.57-2.15 (-0.96%) ▼|T20.81+0.12 (+0.56%) ▲|TMO505.28+4.37 (+0.87%) ▲|TMUS170.88+3.15 (+1.88%) ▲|TSLA422.87+2.27 (+0.54%) ▲|TXN302.33+4.26 (+1.43%) ▲|UBER72.75+0.64 (+0.89%) ▲|UNH418.13+2.78 (+0.67%) ▲|UNP272.74+0.84 (+0.31%) ▲|UPS108.25+0.85 (+0.79%) ▲|USB60.96+0.55 (+0.90%) ▲|V342.20-0.39 (-0.11%) ▼|VZ42.38+0.07 (+0.17%) ▲|WFC84.21+1.57 (+1.90%) ▲|WMT107.91-5.35 (-4.72%) ▼|XOM137.00+0.52 (+0.38%) ▲|
24.8 C
New York
Wednesday, July 1, 2026

Tag: patient

newssourceFORcompanyinformationcontent1releasesmarket

Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPG

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. ("PepGen" or the "Company")...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. – RCKT

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company")...

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published...

Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association’s (ADA) 85th Scientific Sessions and published in NEJM.

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing...

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility and actionable intelligence DENVER, June 22, 2025 /PRNewswire/ --...

New Inclave Casinos 2025: Raging Bull Slots Adds Inclave Payment Solution

Raging Bull has introduced Inclave payment solutions to match its broad gaming library, generous bonuses, and secure login. 
Raging Bull has introduced Inclave payment solutions to match its broad gaming library, generous bonuses, and secure login.

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

ICPO Foundation co-founded the RLT Angels Association with the aim of growing access to Radiotheranostics to one million patients

Further founding members include the European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis, and RayzeBio, a Bristol Myers Squibb company.

MolecuLight Showcases Innovative Multimodal Imaging with Thermal Capabilities at St. Louis Wound & Vascular Symposium

PITTSBURGH, June 21, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, is proud to showcase its presence...

Insurers Suddenly Discover Compassion—Expect a Fine Print Frenzy

As if the insurance industry needed another reminder that it's universally adored, the titans of health coverage are slinking back from their beloved pastime...

Embrace Active Site Care Patch Becomes First Medical Device Clinically Proven to Significantly Improve Lipohypertrophy (LH) in Insulin-Using Diabetes Patients

Findings from 16-week trial of novel compression patch will be shared for the first time at the 85th Scientific Sessions of the American Diabetes...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers